Article Text

Download PDFPDF

COVID-19 presenting as pneumatoceles and spontaneous cavitary lesion as a late complication
  1. Rajesh Kunadharaju and
  2. Alberto Monegro
  1. Pulmonary Critical Care Medicine, University at Buffalo, Buffalo, New York, USA
  1. Correspondence to Dr Rajesh Kunadharaju; drrajesh125{at}


We report a case of an adult patient with COVID-19 pneumonia presenting as pneumatoceles as a late complication. These pneumatoceles are steroid-resistant and can predispose to cavitary lesions. These cystic lesions need close follow-up with repeat imaging as these can increase the risk of pneumothorax. It can take up to around 12 weeks for the spontaneous resolution of pneumatoceles.

  • COVID-19
  • pneumonia (infectious disease)
  • radiology

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


COVID-19 pneumonia is radiographically commonly associated with bilateral patchy peripheral ground glass opacities. Consolidative opacities, septal thickening, pleural thickening are also seen during later stages.1 2 In COVID-19, pneumatoceles and cavitary lesions are rarely reported radiological findings during the progression of the disease.3 4 These are associated with increased risk of pneumothorax and are associated with increased morbidity and mortality.4 5 We report a case of a patient with COVID-19 presenting with steroid-resistant development and rapid progression of pneumatoceles and a spontaneous cavitary lung lesion.

Case presentation

A 62-year-old Caucasian man diagnosed with COVID-19 infection for 2 weeks was admitted to our hospital with complaints of shortness of breath, cough and increased oxygen requirements. His medical history was significant for hyperlipidaemia, benign prostate hypertrophy, gastro-oesophageal reflux disease, anxiety, obstructive sleep apnoea and C4–C7 anterior cervical discectomy and fusion for cervical spondylitis. He is an ex-smoker with less than ten pack-years and quit smoking 20 years ago.

He had initial symptoms of sore throat, dry cough, loss of taste, loss of smell, shortness of breath on exertion, diarrhoea for 8 days, and was admitted to another hospital for COVID-19 pneumonia for 5 days. His initial portable chest X-ray showed subtle interstitial infiltrates. His follow-up CT chest showed a large azygos lobe and patchy ground glass opacities with no significant underlying lung pathology. He was treated with remdesivir and dexamethasone 6 mg for 10 days with improvement in his symptoms. He was discharged on 2 L of oxygen supplementation.

On readmission, his repeat COVID-19 PCR assay was still positive. He was able to speak complete sentences while on high flow oxygen supplementation at fractional inspired oxygen 60% and 25 L per minute flow, and oxygen saturation (SpO2) 96%. He denied any fevers, chills, chest pain, haemoptysis, chest tightness or wheezing. On examination, the patient was noted to have tachycardia, tachypnoea and bilateral crackles on auscultation. His repeat CT chest angiogram showed evidence of multiple thin walled (<2 mm) pneumatoceles surrounding with patchy ground glass opacities compared with the previous CT chest (figure 1).

Figure 1

CT chest–day 19. Arrows represent progressive ground glass and consolidative opacities. Boxes represent cystic changes and cavitary lesions.

Pulmonology and infectious disease were consulted to further evaluate new cystic lesions in the setting of progressive COVID-19 pneumonia. He was empirically treated with board spectrum antibiotics and fluconazole for new cystic lesions.


His initial lab work showed lactate 2.3 mmol/L, lactate dehydrogenase 565 U/L, C reactive protein 5.3 mg/mL, brain natriuretic peptide 11 pg/mL, troponin <0.01 ng/mL and D-dimer 2.15 mcg/mL. On further evaluation, the lab work showed negative streptococcus pneumoniae and legionella urine antigens, procalcitonin was <0.02 ng/mL, beta D glucan levels <31 pg/mL, aspergillus galactomannan <0.5 and had negative blood cultures. Due to a positive COVID-19 test and stable patient’s clinical status, diagnostic bronchoscopy was deferred.

Differential diagnosis

The common differential diagnosis for cystic lung lesions with ground glass opacities are pneumatoceles in the setting of pneumonia, Pneumocystis jirovecii, desquamative interstitial pneumonia and lymphocytic interstitial pneumonitis.5

With the increased use of high-dose steroids in COVID-19, other infectious reasons like P. jirovecii should be considered along with underlying autoimmune disorders like Sjogren’s syndrome and desquamative interstitial pneumonia in patients with current smoking habits. As our patient’s initial CT chest showed no cystic changes, and the patient was noted to have normal beta D glucan levels and had no clinical signs of Sjogren’s syndrome or any other autoimmune disorder, we believe that the CT chest findings were consistent with pneumatoceles in the setting of the progression of the disease due to COVID-19 infection.


The patient was treated with a repeat course of dexamethasone 6 mg, and empiric antibiotics were discontinued due to low suspicion of infection. The patient responded well to steroids with improvement in clinical status and oxygen requirements. He was discharged home with a 2-week prolonged course of dexamethasone 6 mg.

Outcome and follow-up

He had a follow-up CT chest 2 weeks after discharge for cystic lung lesions, which have shown resolution of some pneumatoceles and interval development of new multifocal bilateral cystic lesions and a solitary cavitary lesion measuring 5.9×4.3×4.4 cm in the right lung close to major fissure (figure 2). On the phone follow-up, the patient was stable with no worsening in his symptoms.

Figure 2

CT chest—day 35. Arrows represent progressive ground glass and consolidative opacities. Boxes represent cystic changes and cavitary lesions.

Around 6 weeks after discharge, the patient was seen in the pulmonary clinic as a follow-up. He was still complaining of mild cough and shortness of breath on exertion. He was requiring 1–2 L of oxygen supplementation intermittently during the day and continuously at night. Around 14 weeks after discharge, he was back to his baseline regarding his functional status. His cough improved, and he did not require oxygen supplementation anymore, with SpO2 96% on room air. His repeat CT chest showed improvement in cystic lesions with persistent streaky densities and ground glass opacities (figure 3). His pulmonary function test showed normal spirometry, normal lung volumes with reduced residual volume and mildly reduced diffusing capacity for carbon monoxide (DLCO). His 6 minute walk distance test measured a distance of 480 m with the lowest sat of 95% on exertion with recovery to 100% at rest.

Figure 3

CT chest—day 74. Arrows represent progressive ground glass and consolidative opacities. Boxes represent cystic changes and cavitary lesions.


In COVID-19 pneumonia, lung cavitary lesions are reported as late complications with an increase of pneumothorax.3 4 However, cystic lung lesions are rarely reported in COVID-19 radiologic findings. We present a case of a COVID-19-infected patient with radiological evolution of CT chest findings from mild bilateral ground glass opacities to extensive pulmonary infiltrates and new cystic lung lesions (figure 4). The natural progression of these lesions started as pneumatoceles surrounded by ground glass opacities and progressed to the spontaneous formation of cysts and cavitation in areas separate from prior infiltrates. The large cavitary lesions formed despite being on oral steroids to suggest that these changes were steroid resistant. Although the mechanism for the formation of cystic lesion in COVID-19 pneumonia is not well understood, one potential mechanism is COVID-19-related microthrombi in pulmonary capillaries resulting in ischaemic and inflammatory parenchymal changes and postobstructive alveolar dilatation. The other mechanism is believed to be combination of parenchymal necrosis and check-valve airway obstruction.6

Figure 4

The timeline of the patient’s disease progression. CXR, chest X-ray.

The chest X-ray alone is not adequate to diagnose these cystic lesions as seen with our patient (figure 1), and these patients are at risk of developing cavitary lesions and pneumothorax. A high degree of suspicion for the development of cavitary lesions should be present in patients presenting with pneumatoceles or cystic lung lesions. Repeat imaging in 4–5 weeks after initial symptom onset in patients with new cystic lesions should be considered to avoid undesired consequences of pneumothorax in prolonged intubated patients or patients on noninvasive ventilation for other reasons like obstructive sleep apnoea. In our patient, resolution of pneumatoceles and cavitation occurred in about 12 weeks while off of glucocorticoids.

The late complications of COVID-19 are still largely unknown. With the risk of spontaneous cavitary lesion formation, a close radiological follow-up during a prolonged hospital stay or an outpatient basis after hospital discharge should be considered for better clinical outcomes. There is no clear evidence that steroids would provide any benefit in delaying the progression of these cystic lesions.

Learning points

  • COVID-19 can present with pneumatoceles and ground glass opacities.

  • Pneumatoceles are steroid-resistant and can predispose to cavitary lesions.

  • CT findings of cystic lesions need close follow-up with repeat imaging as these can increase the risk of pneumothorax.

  • Resolution of cystic lesions can take up to 12 weeks.

Ethics statements

Patient consent for publication



  • Contributors RK: author; AM: coauthor and mentor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.